Brandl Talos has advised Allcyte shareholders on the sale of their company to clinical-stage pharmaceutical technology company Exscientia. Cooley LLP and Kunz Wallentin advised Exscientia on the deal.
The transaction remains contingent on regulatory approval.
According to Brandl Talos, "pioneering work by Allcyte has delivered the first clinically validated platform that uses an A.I.-based screening technique to match patients with effective cancer treatments. Therefore, it is possible to select the most promising drug candidates for clinical development to maximize clinical study success rates and patient beneﬁt."
Brandl Talos’s team included Partner Roman Rericha, Attorney Stephan Strass, and Associate Celine Dobnikar.